Actualités

Motley Fool1d agobullish

Is Kailera Therapeutics a Buy After Its Sizzling IPO?

There's a new challenger to the more established players in the weight-loss drug space.

GuruFocus.com10d agobullish

Novo Nordisk Surges 9.2% As Wegovy Pill Fuels Momentum

Novo now expects profit and sales declines of up to 12% this year, better than its earlier 13% forecast.

Simply Wall St.10d agobullish

Insider Monkey10d agobullish

Eli Lilly (LLY) Reports Q1 2026 Revenue Surge of 56% Following FDA Approval of Foundayo

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to invest in for the next 2 years. On April 30, Eli Lilly delivered a powerful performance for Q1 2026, with revenue surging 56% to $19.8 billion. This growth was fueled by a 65% increase in volume, led by the strong demand for […]

LLY

Schaeffer's Investment Research11d agobullish

Signal: Eli Lilly Stock Remains a "Buy" After Earnings

LLY has cleared a historically bullish trendline on the charts

LLY

The Wall Street Journal11d agobullish

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill

Total prescriptions for the new Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

LLY NVO

The Wall Street Journal11d agobullish

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

LLY NVO

Reuters11d agobullish

Novo Nordisk slightly raises outlook as first-quarter profit beats forecast

COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook ‌for the year was slightly improved. The Danish drugmaker is banking on demand for ‌its new weight-loss pill as competition with U.

LLY NVO